Search Results

There are 2963 results for: content related to: Kinase dysfunction and kinase inhibitors

  1. You have free access to this content
    Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours

    Veterinary and Comparative Oncology

    Volume 10, Issue 3, September 2012, Pages: 194–205, C. London, T. Mathie, N. Stingle, C. Clifford, S. Haney, M. K. Klein, L. Beaver, K. Vickery, D. M. Vail, B. Hershey, S. Ettinger, A. Vaughan, F. Alvarez, L. Hillman, M. Kiselow, D. Thamm, M. L. Higginbotham, M. Gauthier, E. Krick, B. Phillips, T. LaDue, P. Jones, J. Bryan, V. Gill, A. Novasad, L. Fulton, J. Carreras, C. McNeill, C. Henry and S. Gillings

    Version of Record online : 1 JUN 2011, DOI: 10.1111/j.1476-5829.2011.00275.x

  2. Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study

    Veterinary and Comparative Oncology

    Volume 10, Issue 3, September 2012, Pages: 174–183, C. Robat, C. London, L. Bunting, L. McCartan, N. Stingle, K. Selting, I. Kurzman and D. M. Vail

    Version of Record online : 31 JAN 2011, DOI: 10.1111/j.1476-5829.2011.00261.x

  3. Pharmacokinetic properties of toceranib phosphate (Palladia™, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors

    Journal of Veterinary Pharmacology and Therapeutics

    Volume 33, Issue 2, April 2010, Pages: 162–171, M. F. YANCEY, D. A. MERRITT, S. P. LESMAN, J. F. BOUCHER and G. M. MICHELS

    Version of Record online : 8 MAR 2010, DOI: 10.1111/j.1365-2885.2009.01133.x

  4. Retrospective evaluation of toceranib phosphate (Palladia®) toxicity in cats

    Veterinary and Comparative Oncology

    C. H. Merrick, J. Pierro, S. E. Schleis, E. A. Sones, Z. M. Wright, R. C. Regan, C. T. Siedlecki and P. J. Bergman

    Version of Record online : 4 APR 2016, DOI: 10.1111/vco.12211

  5. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study

    Veterinary and Comparative Oncology

    Volume 10, Issue 3, September 2012, Pages: 184–193, E. Chon, L. McCartan, L. N. Kubicek and D. M. Vail

    Version of Record online : 21 MAR 2011, DOI: 10.1111/j.1476-5829.2011.00265.x

  6. Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study

    Veterinary and Comparative Oncology

    M. A. Pellin, R. M. Wouda, K. Robinson, K. Tsimbas, I. D. Kurzman, B. J. Biller and D. M. Vail

    Version of Record online : 5 MAY 2016, DOI: 10.1111/vco.12232

  7. You have full text access to this Open Access content
    Clinical and Immunomodulatory Effects of Toceranib Combined with Low-Dose Cyclophosphamide in Dogs with Cancer

    Journal of Veterinary Internal Medicine

    Volume 26, Issue 2, March-April 2012, Pages: 355–362, L. Mitchell, D.H. Thamm and B.J. Biller

    Version of Record online : 4 FEB 2012, DOI: 10.1111/j.1939-1676.2011.00883.x

  8. Distribution, metabolism, and excretion of toceranib phosphate (Palladia™, SU11654), a novel tyrosine kinase inhibitor, in dogs

    Journal of Veterinary Pharmacology and Therapeutics

    Volume 33, Issue 2, April 2010, Pages: 154–161, M. F. YANCEY, D. A. MERRITT, J. A. WHITE, S. A. MARSH and C. W. LOCUSON

    Version of Record online : 8 MAR 2010, DOI: 10.1111/j.1365-2885.2009.01120.x

  9. You have full text access to this Open Access content
    Multicenter Prospective Trial of Hypofractionated Radiation Treatment, Toceranib, and Prednisone for Measurable Canine Mast Cell Tumors

    Journal of Veterinary Internal Medicine

    Volume 26, Issue 1, January-February 2012, Pages: 135–141, K.S. Carlsten, C.A. London, S. Haney, R. Burnett, A.C. Avery and D.H. Thamm

    Version of Record online : 19 DEC 2011, DOI: 10.1111/j.1939-1676.2011.00851.x

  10. You have free access to this content
    European consensus document on mast cell tumours in dogs and cats

    Veterinary and Comparative Oncology

    Volume 10, Issue 3, September 2012, Pages: e1–e29, L. Blackwood, S. Murphy, P. Buracco, J. P. De Vos, P. De Fornel-Thibaud, J. Hirschberger, M. Kessler, J. Pastor, F. Ponce, K. Savary-Bataille and D. J. Argyle

    Version of Record online : 6 AUG 2012, DOI: 10.1111/j.1476-5829.2012.00341.x

  11. PRELIMINARY EVALUATION OF SERIAL 18FDG-PET/CT TO ASSESS RESPONSE TO TOCERANIB PHOSPHATE THERAPY IN CANINE CANCER

    Veterinary Radiology & Ultrasound

    Volume 53, Issue 3, May/June 2012, Pages: 348–357, Amy K. LeBlanc, Ashley N. Miller, Gina D. Galyon, Tamberlyn D. Moyers, Misty J. Long, Alan C. Stuckey, Jonathan S. Wall and Federica Morandi

    Version of Record online : 24 FEB 2012, DOI: 10.1111/j.1740-8261.2012.01925.x

  12. Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia®) in tumour-bearing dogs: a phase I dose-finding study

    Veterinary and Comparative Oncology

    Volume 14, Issue 2, June 2016, Pages: 202–209, X. Pan, K. Tsimbas, I. D. Kurzman and D. M. Vail

    Version of Record online : 15 APR 2014, DOI: 10.1111/vco.12091

  13. Advances in the management of skin cancer

    Veterinary Dermatology

    Volume 24, Issue 1, February 2013, Pages: 173–e38, Pamela D. Martin and David J. Argyle

    Version of Record online : 19 JAN 2013, DOI: 10.1111/j.1365-3164.2012.01107.x

  14. Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy

    Veterinary and Comparative Oncology

    Volume 10, Issue 3, September 2012, Pages: 163–173, S. Bavcar and D. J. Argyle

    Version of Record online : 6 AUG 2012, DOI: 10.1111/j.1476-5829.2012.00342.x

  15. Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours

    Veterinary and Comparative Oncology

    Volume 8, Issue 3, September 2010, Pages: 209–220, E. K. Malone, K. M. Rassnick, J. J. Wakshlag, D. S. Russell, R. Al-Sarraf, D. M. Ruslander, C. S. Johnson and D. L. Trump

    Version of Record online : 24 JUN 2010, DOI: 10.1111/j.1476-5829.2010.00223.x

  16. The tyrosine kinase inhibitor toceranib in feline injection site sarcoma: efficacy and side effects

    Veterinary and Comparative Oncology

    N. Holtermann, M. Kiupel and J. Hirschberger

    Version of Record online : 14 JAN 2016, DOI: 10.1111/vco.12207

  17. Comparison of chemotherapeutic drug resistance in cells transfected with canine ABCG2 or feline ABCG2

    Veterinary and Comparative Oncology

    R. S. Lewis, J. Fidel, S. Dassanayake, M. H. Court, N. S. Burke and K. L. Mealey

    Version of Record online : 14 OCT 2015, DOI: 10.1111/vco.12177

  18. You have full text access to this OnlineOpen article
    2016 ACVIM Forum Research Abstract Program

    Journal of Veterinary Internal Medicine

    Volume 30, Issue 4, July/August 2016, Pages: 1407–1519,

    Version of Record online : 31 MAY 2016, DOI: 10.1111/jvim.13952

  19. Primary frontal sinus squamous cell carcinoma in three dogs treated with piroxicam combined with carboplatin or toceranib

    Veterinary and Comparative Oncology

    Volume 10, Issue 3, September 2012, Pages: 206–213, J. de Vos, S. Ramos Vega, E. Noorman and P. de Vos

    Version of Record online : 30 AUG 2011, DOI: 10.1111/j.1476-5829.2011.00292.x

  20. Expression of PDGFR-β and Kit in canine anal sac apocrine gland adenocarcinoma using tissue immunohistochemistry

    Veterinary and Comparative Oncology

    Volume 10, Issue 1, March 2012, Pages: 74–79, R. J. Brown, S. J. Newman, D. C. Durtschi and A. K. LeBlanc

    Version of Record online : 3 AUG 2011, DOI: 10.1111/j.1476-5829.2011.00286.x